Archives for April 2011

The mafia approach

A recent study from the Archives of Internal Medicine proves (once again) that Big Pharma buys guideline panels the same way that the mafia buys juries.

Bribes and recalls

The feds say Johnson & Johnson’s in-house crooks used those bribes to sell implants in Greece and prescriptions in Romania, and to win contracts in Poland.

Diabetes patients more likely to die of cancer

Researchers from the National Cancer Institute examined data on 500,000 people between the ages of 50 and 61 who were tracked for 11 years, and found that diabetes increased the risk of death by cancer in women by 11 percent, and in men by 17 percent.

BPA’s lasting effects

This hormone-like chemical is in you, right now, and there’s not much you can do about it: A new study finds you can completely cut out all foods from BPA-laced containers and STILL have plenty of this junk left over days later.

The unbelievable surge in medical mistakes

If you’re sick or injured, the last place you want to be is a hospital, where up to a third of all patients are victim of some form of medical screw-up, according to a new study.

Broken hearts & shattered lives

A new study finds that men who take antidepressants end up with arteries so thick and hard you may as will line your insides with PVC pipe… and while that may be great for toilets, it can mean serious heart risk when it comes to your internal tubing.

Children’s CT scans skyrocket

I just don’t get it: Americans are panicking over the theoretical threat of radiation floating over here from Japan — and ignoring the very real threats we face every day.

New cancer fears at the airport

It’s not often I’m on the same page as the American Cancer Society — but their chief medical officer is taking a page out of my book, and I couldn’t be happier about it.

Researchers confirm Avandia risk

Researchers say Avandia can up your risk of heart attack, heart failure, and an early death.

Drugs for diabetes prevention

With all the hoopla over the diabetes drug Avandia lately, its major competitor — Actos — is being handed the golden ticket.